SCHEMBL4402279

SCHEMBL4402279

COc1ccc(CCOc2cc(NN)cc(N3CCOCC3)n2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALOX15 P16050 2/20 0.51
ELOVL1 Q9BW60 2/20 0.44
MAPT P10636 2/20 0.44
CSF1R P07333 4/20 0.44
KIT P10721 3/20 0.44
PDE4B Q07343 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE11A Q9HCR9 1/20 0.43
TYK2 P29597 1/20 0.42
SYK P43405 1/20 0.42
BRSK1 Q8TDC3 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4400048 0.85 MEN1 (0.51) MEN1KMT2AALOX15ELOVL1MAPT
SCHEMBL424029 0.80 PIKFYVE (0.54) MEN1KMT2AALOX15MAPTTYK2
SCHEMBL2672964 0.80 CSF1R (0.42) MEN1KMT2AALOX15MAPTCSF1R
SCHEMBL430889 0.77 NPC1 (0.53) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL425047 0.77 MAPT (0.46) MEN1KMT2AALOX15MAPTCSF1R
SCHEMBL4402163 0.77 MAPT (0.46) MEN1KMT2AALOX15MAPTCSF1R
SCHEMBL425048 0.77 MAPT (0.46) MEN1KMT2AALOX15MAPTCSF1R
SCHEMBL4406713 0.77 KMT2A (0.51) MEN1KMT2AALOX15ELOVL1MAPT
SCHEMBL1374503 0.75 MEN1 (0.52) MEN1KMT2AALOX15MAPTCSF1R
SCHEMBL2672248 0.73 MEN1 (0.45) MEN1KMT2AALOX15MAPTCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-20100173413-A1 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-07-08 US disclosed
US-20100173413-A1 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-07-08 US disclosed
US-7687498-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687498-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2010-03-30 US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167300-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 MEN1 2681/4885KMT2A 3258/4885ALOX15 325/4885
US-20100173413-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 MEN1 2681/4885KMT2A 3258/4885ALOX15 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.